PET imaging of SV2A: Rabiner provides an overview of recent developments in PET ligands for the synaptic vesicle glycoprotein 2A and the potential for investigating and monitoring brain pathology involving synaptic dysfunction. ***Page 380***

Chelate-free radiochemistry: Lamb and Holland review the evolution of nanoparticle radiochemistry and present 9 mechanistically distinct advanced methods for radiolabeling multimodality nanomedicines for SPECT/MR and PET/MR imaging. ***Page 382***

Dual-targeted molecular imaging: Ehlerding and colleagues outline the ways in which peptide-, antibody-, and nanoparticle-based platforms have affected the development of synergistic molecular targeting with 2 ligands. ***Page 390***

UEMS/EBNM and education: Frangos and colleagues from the European Union of Medical Specialists and the European Board of Nuclear Medicine offer commentary on activities supporting educational and certification standards for nuclear medicine specialists. ***Page 396***

Within-suite ^{89}Zr PET/CT-guided biopsy: Cornelis and colleagues evaluate the feasibility of within-suite ^{89}Zr-labeled PET/CT-guided biopsy performed without reinjection in metastatic prostate or breast cancer. ***Page 399***

^{68}Ga-DOTA-RGD and nintedanib in NSCLC: Arrieta and colleagues investigate the potential of PET/CT imaging with this $\alpha_v\beta_3$ integrin−targeting tracer for monitoring treatment response with nintedanib, an oral angiokinase inhibitor, in patients with non–small cell lung cancer. ***Page 403***

Imaging immunotherapy workshop report: Shields and colleagues summarize the results of a May 2016 workshop at the National Cancer Institute on immune-modulation therapies and the most promising foci for imaging in clinical trials. ***Page 410***

Battle for PET reimbursement: Hicks provides commentary on the long-running and global efforts to achieve more broadly based reimbursement for PET applications and provides context for 3 articles in this month's issue of *JNM*. ***Page 418***

Patient management after NaF PET: Hillner and colleagues use data from the National Oncologic PET Registry to assess the concordance of intended patient management after NaF PET imaging and inferred management based on analysis of Medicare claims. ***Page 421***

NaF PET and hospice care/survival: Gareen and colleagues use Medicare administrative data linked to the National Oncologic PET Registry to examine associations between NaF PET results and hospice claims within 180-d and 1-y survival periods. ***Page 427***

^{68}Ga-PSMA-11 PET/CT and management: Calais and colleagues detail the results of a survey of referring physicians on whether and how ^{68}Ga-labeled prostate-specific membrane antigen 11 PET/CT imaging affects the implemented management of prostate cancer patients with biochemical recurrence. ***Page 434***

Alternative copper-based PET in prostate cancer: Ceci and colleagues provide perspective on the proposed use of $^{64}CuCl_2$ PET imaging in patients with biochemical recurrence and preview an article on this topic in this issue of *JNM*. ***Page 442***

$^{64}CuCl_2$ PET/CT in prostate cancer: Piccardo and colleagues report on the biodistribution, kinetics, and radiation dosimetry of this tracer in humans and on the ability of $^{64}CuCl_2$ PET/CT to detect prostate cancer recurrence in patients with biochemical relapse. ***Page 444***

Hematologic dysfunction after PRRT: Bergsma and colleagues analyze persistent hematologic dysfunction after peptide-receptor radionuclide therapy with ^{177}Lu-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumors. ***Page 452***

^{177}Lu-PSMA-617 dose escalation: Rathke and colleagues detail clinical observations on 4 different treatment activities of ^{177}Lu-labeled prostate-specific membrane antigen–617 in patients with advanced prostate cancer. ***Page 459***

Proposed prostate PSMA PET criteria: Cho offers perspective and background on 2 new proposed prostate-specific membrane antigen PET criteria detailed in this issue of *JNM* and designed to facilitate prostate cancer reporting and classification. ***Page 466***

miTNM for PSMA-ligand PET/CT: Eiber and colleagues describe development of a molecular imaging TNM system as a standardized reporting framework for prostate-specific membrane antigen–ligand PET/CT or PET/MR imaging. ***Page 469***

PSMA-RADS 1.0: Rowe and colleagues propose a structured reporting and data system for findings on prostate-specific membrane antigen–targeted PET studies, with anticipated results in improving the consistency of clinical data generated in these studies. ***Page 479***

PSMA imaging in nonprostate cancers: Nimmagadda and colleagues describe prostate-specific membrane antigen expression in nonprostatic epithelial cells from publicly available genomic databases and characterize the potential of PSMA-binding agents to noninvasively detect that expression. ***Page 486***

Anti-PSMA ADC for prostate cancer: Lütje and colleagues explore the preclinical therapeutic efficacy of site-specifically conjugated duocarmycin- and monomethyl auristatin E–based anti–prostate-specific membrane antigen antibody–drug conjugates with differing drug-to-antibody ratios ***Page 494***

Curie score in high-risk neuroblastoma: Yanik and colleagues report on independent validation of the postinduction ^{123}I-MIBG Curie scoring method in predicting treatment outcomes in children with high-risk neuroblastoma. ***Page 502***

β-amyloid and neuroinflammation in AD: López-Picón and colleagues evaluate longitudinal changes and correlations in β-amyloid deposition and neuroinflammation using ^{11}C-PIB and ^{18}F-GE-180 PET in a mouse model of Alzheimer disease. ***Page 509***

IRT vs. PET/CT in BAT: Law and colleagues compare the accuracy of infrared thermography with that of ^{18}F-FDG PET/CT in assessing brown adipose tissue activation in a group of healthy men. ***Page 516***

PET/MR in pituitary microadenoma: Wang and colleagues assess the ability of PET/MR imaging, using ^{18}F-FDG and ^{68}Ga-DOTATATE as tracers, to detect hormone-producing pituitary microadenoma when diagnosis is challenging with MR alone. ***Page 523***

^{18}F-labeled anti–PD-L1 adnectin: Donnelly and colleagues describe in vitro and preclinical in vivo PET imaging studies of tumor targeting of an anti–programmed death protein ligand adnectin after ^{18}F-fluorine labeling. ***Page 529***

Preclinical PET/MR insert: Stortz and colleagues characterize and validate a compact MR-compatible PET insert for simultaneous, high-resolution small animal PET and MR imaging at 7T. ***Page 536***